Ecliptasaponin A
Based on 1 Customer Validation
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.
For research use only. We do not sell to patients.
- Purity : 99.81%
- CAS No.: 78285-90-2
- Formula: C36H58O9
- Molecular Weight:634.84
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
Description
|
MMP-9 |
MMP-13 |
MMP-2 |
NF-κB |
COX-2 |
TLR4 |
In Vitro
Ecliptasaponin A (5-20 μM) inhibits the HMGB1/TLR4/NF-κB pathway to play a protective role on H9C2 cells of oxygen-glucose deprivation (OGD)[3].
Ecliptasaponin A (0-120 μM, 24-48 h) exhibits dose- and time-dependent inhibition of H460 and H1975 cells viability and colony formation ability[4].
Ecliptasaponin A (0-30 μM, 24 h) induces apoptosis through the activation of ASK1/JNK pathway and autophagy in H460 and H1975 cells[4].
Ecliptasaponin A (5-30 μM, 48 h) inhibits ECM and MMP13 expression in human kidney-2 (HK-2) cells induced by transforming growth factor-beta1 (TGFβ1)[5].
Ecliptasaponin A (0-25 μM) targets the protein ESR1 to increase the viability and reduce apoptosis in Cyclophosphamide (HY-17420)-induced damage in AW-CCH252 cells[6].
Ecliptasaponin A (10-50 ng/mL, 25 h) shows the reduced expression of all osteoarthritis -related molecules in IL-1β-stimulated SW1353 cells[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H460 and H1975 cells
-
Concentration:0, 20, 40, 60, 80, 100 and 120 μM
-
Incubation Time:24 and 48 h
-
Result:Significantly induced cell death in both dose-dependent and time-dependent ways.
-
Cell Line:H460 and H1975 cells
-
Concentration:0, 10, 20 and 30 μM
-
Incubation Time:24 h
-
Result:Dose-dependently increased the proportion of apoptotic cells, with early apoptosis (Annexin V+/PI-) being the predominant type.
Displayed typical apoptotic features: nuclear shrinkage, chromatin condensation, nuclear fragmentation, and the formation of apoptotic bodies.
-
Cell Line:H460 and H1975 cells
-
Concentration:0, 10, 20 and 30 μM
-
Incubation Time:24 h
-
Result:Increased the Caspase-3/8/9 cleavage products and PARP cleavage.
Increased the LC3-II/I ratio, upregulated Beclin-1 expression, and accelerated the degradation of p62.
Increased the expression of p-ASK1 and p-JNK, and decreased the expression of p-ERK.
-
Cell Line:HK-2 cells
-
Concentration:20 nM
-
Incubation Time:48 h
-
Result:Inhibited the protein expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Specifically inhibited MMP13 rather than MMP10.
Inhibited Col-1, α-SMA, and CTGF.
-
Cell Line:HK-2 cells
-
Concentration:5, 10, 15, 20, 25, 30 nM
-
Incubation Time:48 h
-
Result:Decreased the expression of type I collagen in a concentration-dependent manner.
Inhibited the gene expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Significantly inhibited the mRNA expression of MMP10 (not obvious) and MMP13.
-
Cell Line:SW1353 cells
-
Concentration:10, 30, 50 ng/mL
-
Incubation Time:Pretreated at 1 h before IL-1β stimulation (24 h) for 25 h
-
Result:Decreased the mRNA expression of OA-related molecules (MMP13, TNF-α, IL-1β, COX1/2).
-
Cell Line:SW1353 cells
-
Concentration:10, 30, 50 ng/mL
-
Incubation Time:Pretreated at 1 h before IL-1β stimulation (24 h) for 25 h
-
Result:Decreased the protein expression of OA-related molecules (MMP13, Collagen type II, TNF-α, IL-1β, and COX-2).
Parmacokinetics
In Vivo
Ecliptasaponin A (80 mg/kg, p.o., once daily for 28 days) prevents the fibrosis in mice via inhibiting TGF-β1 expression[2].
Ecliptasaponin A (0.5-2.5 mg/kg, intramyocardial injection of the left ventricular myocardium, single dose) demonstrates a cardiac protective role in acute myocardial infarction (AMI) model in mice[3].
Ecliptasaponin A (25-50 mg/kg, i.p., for 21 days) causes a clear suppression of tumor growth in lung cancer-bearing nude mice[4].
Ecliptasaponin A (80 mg/kg, p.o., once daily for 10 days) reduces the renal collagen fiber deposition and renal extracellular matrix (ECM) protein expression in renal fibrosis unilateral ureteral obstruction (UUO) mice[5].
Ecliptasaponin A (200 mg/mL with Specnuezhenide (HY-N0665), p.o., once daily for 30 days) improves the basal characteristics and sex hormone levels premature ovarian failure (POF) mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pulmonary fibrosis model induced by Bleomycin (HY-108345) established in adult male ICR mice (6-7 weeks)[2]
-
Dosage:80 mg/kg
-
Administration:Oral administration (p.o.), once daily for 28 days
-
Result:Blocked BLM-induced histological changes of lung tissue.
Decreased the high levels of TGF-β1 and α-SMA.
-
Animal Model:AMI model induced by underwent left anterior descending coronary artery (LAD) ligation established in male SPF C57/BL6 mice, aged 8-10 weeks and weighing 23-25 g[3]
-
Dosage:0.5, 1.25, and 2.5 mg/kg
-
Administration:Intramyocardial injection of the left ventricular myocardium, single dose
-
Result:Significantly improved ejection fraction (EF%) and short-axis shortening rate (FS%).
Significantly reduced the area of myocardial infarction.
Reduced myocardial cell apoptosis and inflammatory cell infiltration.
Significantly reduced the expressions of HMGB1 and TLR4, as well as the phosphorylation of p-IkBα and p-P65, and the levels of inflammatory factors IL-1β, IL-6, and TNF-α.
Significantly enriched HMGB1/TLR4/NF-κB pathway.
-
Animal Model:H460 cells induced xenograft tumor model established in male BALB-c nude mice (4-week-old)[4]
-
Dosage:25 and 50 mg/kg
-
Administration:Intraperitoneal injection (i.p.), for 21 days
-
Result:Decreased the tumor weight and volume.
No significant biological toxicity.
-
Animal Model:Renal fibrosis UUO model established in six-week-old C57BL/6 J mice[5]
-
Dosage:80 mg/kg
-
Administration:Oral administration (p.o.), once daily for 10 days
-
Result:Ameliorated the obstructive kidney weight ratio.
Attenuated histological damage and collagen deposition in the kidneys.
-
Animal Model:POF model established in SPF-grade female C57 mice, 6-8 weeks[6]
-
Dosage:200 mg/mL with Specnuezhenide
-
Administration:Oral administration (p.o.), once daily for 30 days
-
Result:Increased the ovarian index and serum estradiol (E2) levels.
Reduced the level of follicle-stimulating hormone (FSH).
Extended the emotional cycle.
Increased the number and diameter of follicles.
Promoted ovarian angiogenesis (increase the expression of CD31 and VEGFA).
Chemical Information
-
CAS No. 78285-90-2
-
Appearance Solid
-
Molecular Weight 634.84
-
Formula C36H58O9
-
Color White to off-white
-
SMILES
CC1(C)[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)CC[C@]3(C)[C@@]4([H])CC=C5[C@]6([H])CC(C)(C)CC[C@@](C(O)=O)6[C@H](O)C[C@](C)5[C@@](C)4CC[C@@]13[H]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (157.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (292 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Du G, et al. Validated UPLC-MS/MS method for quantification of seven compounds in rat plasma and tissues: Application to pharmacokinetic and tissue distribution studies in rats after oral administration of extract of Eclipta prostrata L. Biomed Chromatogr. 2018 Jun;32(6):e4191. [Content Brief]
[3]. Ge S, et al. Ecliptasaponin A protects heart against acute ischemia-induced myocardial injury by inhibition of the HMGB1/TLR4/NF-κB pathway. J Ethnopharmacol. 2024 Dec 5;335:118612. [Content Brief]
[4]. Han J, et al Ecliptasaponin A induces apoptosis through the activation of ASK1/JNK pathway and autophagy in human lung cancer cells. Ann Transl Med. 2019 Oct;7(20):539. [Content Brief]
[5]. Li X, Dong W, Yang Y, Ren S, Wang X, Zou M, Lu W, Liu L, Xue Y. Ecliptasaponin A attenuates renal fibrosis by regulating the extracellular matrix of renal tubular cells. In Vitro Cell Dev Biol Anim. 2023 Oct;59(9):684-696. doi: 10.1007/s11626-023-00803-0. Epub 2023 Oct 13. PMID: 37831322; PMCID: PMC10709264. [Content Brief]
[6]. Xu J, et al. Specnuezhenide and ecliptasaponin A from Ligustrum lucidum Ait and Ecliptae Herba improved premature ovarian failure by targeting the ESR1. J Pharmacol Sci. 2025 May;158(1):13-26. [Content Brief]
[7]. Hong GU, et al. Inhibition of Osteoarthritis-Related Molecules by Isomucronulatol 7-O-β-d-glucoside and Ecliptasaponin A in IL-1β-Stimulated Chondrosarcoma Cell Model. Molecules. 2018 Oct 29;23(11):2807. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5752 mL | 7.8760 mL | 15.7520 mL | 39.3800 mL |
| 5 mM | 0.3150 mL | 1.5752 mL | 3.1504 mL | 7.8760 mL | |
| 10 mM | 0.1575 mL | 0.7876 mL | 1.5752 mL | 3.9380 mL | |
| 15 mM | 0.1050 mL | 0.5251 mL | 1.0501 mL | 2.6253 mL | |
| 20 mM | 0.0788 mL | 0.3938 mL | 0.7876 mL | 1.9690 mL | |
| 25 mM | 0.0630 mL | 0.3150 mL | 0.6301 mL | 1.5752 mL | |
| 30 mM | 0.0525 mL | 0.2625 mL | 0.5251 mL | 1.3127 mL | |
| 40 mM | 0.0394 mL | 0.1969 mL | 0.3938 mL | 0.9845 mL | |
| 50 mM | 0.0315 mL | 0.1575 mL | 0.3150 mL | 0.7876 mL | |
| 60 mM | 0.0263 mL | 0.1313 mL | 0.2625 mL | 0.6563 mL | |
| 80 mM | 0.0197 mL | 0.0984 mL | 0.1969 mL | 0.4922 mL | |
| 100 mM | 0.0158 mL | 0.0788 mL | 0.1575 mL | 0.3938 mL |